CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.3% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade Gilead GILD

Gilead live chart

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

Gilead news

Latest news

Show more

Info

Spread

0.93

Spread (%)

0.6283 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Wednesday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

182029500416

Shares Outstanding

1241420528

Earnings Date (Next)

2013-01-28

Div Yield

2026-03-30

Ex-Dividend Date

2026-03-13

Forward annual dividend rate

3.28

Forward annual dividend yield

0.0224

EPS

6.77

Learn more about this instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Related Instruments

Asset
Sell
Buy
Change (%)
View all instruments

Latest Education Articles

Show more
Trustpilot